Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma - Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center

Jesko Momotow; Helen Goergen; Karolin Behringer; Paul J Bröckelmann; Sven Borchmann; Bastian V Tresckow; Carsten Kobe; Andreas Engert; Stephanie Sasse

doi:10.1097/HS9.0000000000000293

Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma - Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center

Hemasphere. 2019 Sep 27;3(4):e293. doi: 10.1097/HS9.0000000000000293. eCollection 2019 Oct.

Authors

Jesko Momotow^{1

2}, Helen Goergen^{1

2}, Karolin Behringer^{1

2}, Paul J Bröckelmann^{1

2}, Sven Borchmann^{1

2

3

4}, Bastian V Tresckow^{1

2}, Carsten Kobe^{2

5}, Andreas Engert^{1

2}, Stephanie Sasse^{1

2}

Affiliations

¹ Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne.
² German Hodgkin Study Group (GHSG).
³ Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Center for Molecular Medicine, University of Cologne.
⁴ Faculty of Medicine, Else Kröner Forschungskolleg Clonal Evolution in Cancer, University of Cologne.
⁵ Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany.

No abstract available

Publication types

Letter